Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Hypothetical protein | 0.235 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2828 | 0.4946 | 0.321 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2828 | 0.4946 | 0.321 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.235 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3981 | 1 | 1 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.3981 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.2828 | 0.4946 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Loa Loa (eye worm) | TKL/MLK/LZK protein kinase | 0.2828 | 0.4946 | 0.321 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.235 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.3981 | 1 | 1 |
Onchocerca volvulus | 0.3981 | 1 | 0.5 | |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.3914 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3914 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.235 | 0.2852 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3914 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3914 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | hypothetical protein | 0.235 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.3914 | 0.9706 | 0.9604 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.